Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for inhibiting growth of enterococcus faecium

A technology of Enterococcus faecium and drugs, which is applied in the field of antibacterial research of Enterococcus faecium, to achieve the effect of solving the problem of drug resistance and infection, reducing the fatality rate, and wide application value

Inactive Publication Date: 2020-07-17
济宁市第一人民医院
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the serious drug resistance of Enterococcus faecium has brought great challenges to clinical treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for inhibiting growth of enterococcus faecium
  • Medicine for inhibiting growth of enterococcus faecium
  • Medicine for inhibiting growth of enterococcus faecium

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1 Drug susceptibility test of Enterococcus faecium

[0016] Human Enterococcus faecium (strain samples were taken from Beijing Haidian Hospital) as the starting strain, penicillin G, ampicillin, levofloxacin, erythromycin, teicoplanin, vancomycin, and linezolid were used for test;

[0017] Pick out the pure colonies cultured for 18-24h and dissolve them in 2-5mL sterile saline, and adjust the turbidity to match the turbidity of a 0.5 McFarland turbidimetric tube. The antibiotics, bacterial liquid and TSB liquid medium were added to the 96-well culture plate overnight by the double dilution method of the test tube, and the groups of different concentrations of the liquid were three parallel to ensure the reliability of the experimental data;

[0018] The minimum inhibitory concentration of sanguinarine against Enterococcus faecium was determined by microplate reader. The culture solution under the minimum inhibitory concentration was placed in sterile LB liquid...

Embodiment 2

[0023] Example 2 Inhibitory effect of sanguinarine on multidrug-resistant strains

[0024] Pick the pure colonies cultivated overnight and dissolve them evenly in 10 mL of TSB liquid medium, adjust their turbidity to equal turbidity in a 0.5 McFarland turbidimetric tube, and measure their OD with a microplate reader. 600 value. Using dimethyl sulfoxide to prepare sanguinarine with a concentration of 1000 μg / mL as the medicinal solution, the medicinal solution, bacterial fluid and TSB liquid medium were added to the 96-well culture plate by the double dilution method of the test tube for overnight culture. The liquid groups are all in parallel to ensure the reliability of the experimental data.

[0025] The minimum inhibitory concentration (MIC) of sanguinarine against Enterococcus faecium was determined by a microplate reader, and the MIC concentration was used as a reference to add a drug dilution gradient to the cultured bacterial solution, and the corresponding culture sol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses a medicine for inhibiting the growth of enterococcus faecium. The medicine comprises sanguinarine. According to the invention, a potential drug-resistant bacteria inhibitor isexcavated from an existing medicinal plant resource library. Based on the research of the action of the sanguinarine on enterococcus faecium, the invention discovers that the non-antibiotic compound sanguinarine can effectively inhibit the growth of the enterococcus faecium, provides a new thought and source for the research, development and application of an enterococcus faecium inhibitor, and has wide application value in the fields of medicines and the like. According to the invention, the inhibition effect of the sanguinarine on the enterococcus faecium is determined, and the sanguinarineis used as an antibiotic substitute, can effectively relieve or solve the problems of drug resistance and infection of the enterococcus faecium, and reduces the mortality.

Description

technical field [0001] The invention belongs to the research field of Enterococcus faecalis bacteriostatic research, in particular to a medicine for inhibiting the growth of Enterococcus faecium. Background technique [0002] Enterococcus Faecium belongs to the genus Enterococcus and is a Gram-positive bacterium that is part of the normal flora in the human and animal intestines. At present, there is no good specific medicine for the treatment of Enterococcus faecium, but penicillin and streptomycin can be used for treatment. At the same time, Enterococcus is also very easy to develop drug resistance, and its drug resistance includes three kinds of intrinsic drug resistance, acquired drug resistance and tolerance. Because of their strong cell walls, enterococci are inherently resistant to many antibiotics. Due to the difficulty of treatment of drug-resistant infections caused by these bacteria, and the complex drug resistance of enterococci to antibiotics, many of the ente...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4741A61P31/04
CPCA61K31/4741A61P31/04
Inventor 孔毅丁琳李仁哲魏文婷耿芝苏磊卢太红杨名名
Owner 济宁市第一人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com